摘要目的前瞻性研究动态MR增强扫描时,乳腺癌的强化、良性强化性病变(BEL)和背景实质增强(BPE)在含紫杉烷新辅助化疗(T-NACT)与不含紫杉烷新辅助化疗(NACT,NT-NACT)中的影响。材料与方法该研究得到伦理委员会批准,2008年—2011年间62例浸润性乳腺癌病人接受含紫杉烷(n=49)及不含紫杉烷(n=13)的多主体新辅助化疗。所有病人均填写书面知情同意书。所有病人在NACT之前和化疗后2周根据标准化协议,进行动态增强MR扫描。通 Abstract Objective To prospectively study the effect of breast enhancement, benign enhancement lesion (BEL) and background enhancement (BPE) in patients undergoing dynamic MR-enhanced MR imaging with or without taxane neoadjuvant chemotherapy (T-NACT) Effect of adjuvant chemotherapy (NACT, NT-NACT). MATERIALS AND METHODS The study was approved by the Ethics Committee and 62 patients with invasive breast cancer received multi-agent neoadjuvant chemotherapy with taxane (n = 49) and no taxane (n = 13) during 2008-2011. All patients have written written informed consent. All patients underwent dynamic contrast-enhanced MR scans prior to NACT and 2 weeks after chemotherapy according to a standardized protocol. through